Ovarian Cancer

Rezatapopt hit a 46% ORR in TP53 Y220C–mutated ovarian cancer in the PYNNACLE trial, with an FDA filing expected in Q1 2027.

The final recommendations were directly shaped by data from 36 published articles.

The FDA gave fast track designation to the anti-TNFR2 agent in combination with pembrolizumab in advanced platinum-resistant ovarian cancer.

Large Ontario cohort study finds lifetime breast and ovarian cancer risk varies sharply by BRCA1/BRCA2 test result, including in those with inconclusive or negative findings.

Early phase 2 data show IMNN-001 added to chemo plus bevacizumab reduces residual ovarian cancer, boosts ctDNA clearance, and remains well tolerated.

ROSELLA update shows consistent OS benefit with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, irrespective of prior taxane use.

Intraperitoneal rintatolimod may boost outcomes with immunotherapies such as pembrolizumab in ovarian cancer.

Robert Coleman, MD, discusses how relacorilant plus nab‑paclitaxel boosts survival in platinum‑resistant ovarian cancer.

Dr Alexander Olawaiye discusses the impact of the FDA approval of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Premal Thaker, MD, MS, discusses IMNN-001 boosts overall survival in advanced ovarian cancer, with bigger gains alongside PARP inhibitors, as phase 3 OVATION 3 ramps up.

Rezatapopt showed clinical activity across subgroups in patients with TP53 Y220C-mutated ovarian cancer in the phase 2 PYNNACLE trial.

Enrollment restarts in a phase 2 ovarian and clear cell gynecologic cancer study after FDA lifts hold on PD-1/CTLA-4 DART therapy.

Mirvetuximab soravtansine plus carboplatin showed promise in patients with FRα-positive platinum-sensitive ovarian cancer.

The novel FRα-targeted ADC sofetabart mipitecan showed strong antitumor activity in patients with heavily pretreated platinum-resistant ovarian cancer.

Final ROSELLA overall survival results show adding relacorilant to nab-paclitaxel reduces risk of death by 35% in platinum-resistant ovarian cancer.

FDA grants fast track designation to SIM0505, a CDH6-targeting ADC, for platinum-resistant ovarian cancer. Phase 1 data expected at ASCO 2026.

FDA fast track status for CTIM-76 underscores the unmet need in platinum-resistant ovarian cancer.